Granulocyte-Colony Stimulating Factor
human, recombinant, E. coli
For in vitro use only!
Shipping: shipped at ambient temperature
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 19 kDa
Accession number: P09919
Accession number: P09919
Purity: > 95 % (SDS-PAGE, RP-HPLC)
Form: lyophilised (G-CSF was lyophilised after dialysis against 10 mM sodium acetate pH 4.0)
Solubility: It is recommended to reconstitute the lyophilised G-CSF in sterile bidest H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Activity: ED50: < 0.1 ng/ml corresponding to a specific activity of 1 x 108 IU/mg, calculated by the dosedependant proliferation of murine NFS-60 indicator cells (measured by 3H-thymidine uptake).
G-CSF is a glycoprotein with a molecular weight of 20 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, Interleukin-1, and GM-CSF (cat.# PR-436 or PR-437). Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by Interleukin-17. Recombinant human G-CSF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 18.8 kDa. Recombinant G-CSF is purified by proprietary chromatographic techniques.
Endotoxin: Less than 0.1 ng/μg (IEU/μg) of G-CSF.
Worden et al. (2005) Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J. Clin. Oncol. 23:105.
Lozano et al. (2004) Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors. Transfusion 44:1755.
Youssef et al. (2004) Effect of bovine granulocyte colony-stimulating factor on the development of pneumonia caused by Mannheimia haemolytica. Vet. Pathol. 41:649.
Hisashi et al. (2004) Granulocyte-colony stimulating factor enhanced the recruitment of bone marrow cells into the heart: time course evaluation of phenotypic differentiation in the doxorubicin-induced cardiomyopathic model. Jpn. J. Thorac. Cardiovasc. Surg. 52:451.
Jorgensen et al. (2005) Granulocyte-colonystimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103:210.
Kleinschnitz et al. (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res. Mol. Brain Res. 131:73.